Kinetics studies of phytomedicine mathesia - -butyrolactone interaction

  • Authors

    • L. H. Nkasa Université de Kinshasa
    • M. C. Mulenga Université de Kinshasa
    • M. J. Muzomwe Université de Kinshasa
    • S. J. Kayembe Université de Kinshasa
    • L. B. Ilinga Université de Kinshasa
    • M. Z. Kashongwe Université de Kinshasa
    • B. P. Ngoy Université de Kinshasa
    • K. M Taba Université de Kinshasa
    2022-06-07
    https://doi.org/10.14419/ijet.v11i1.32057
  • Mycobacterium Ulcerans, Mycolactone, Γ-Butyrolactone, Buruli Ulcer, Mathesia.
  • Kinetic studies of the interaction between  γ-Butyrolactone and one of the phytomedecines such as Mathesia used for Buruli ulcer treatment were investigated by conductimetry. γ-Butyrolactone which is the simplest form of lactone was used as probe in order to fully understand how a cyclic ester, such as lactone, could behave in a basic environment. It was observed that for the Mathesia solution at pH 11 the minimal apparent rate constant was around 3.54636 compare to sodium hydroxyde solution at pH 12 where the minimal apparent rate constant was around 3.12295. The apparent rate constants of successive diluted solutions of Phytomedicine Mathesia show up the dilution factor 1: 4. A plot of apparent rate constant versus dilution factor gave a curve with a correlation coefficient of 0.99831.

  • References

    1. [1] Portaels F., Elsen P., Guimaraes Peres A. (1999). Insects in the transmission of Mycobacterium ulcerans infection (Buruli ulcer.) The Lancet 353:986. https://doi.org/10.1016/S0140-6736(98)05177-0.

      [2] Aguiar J., Domingo MC., Guegueson A., Meyers WM., see and Portaels F. (1997). Buruli ulcer: A major Mycobacterial disease and an upsurge in Benin. Bull séanc Acad. R SCI Overseas, 43,325-338.

      [3] Aguiar J and Steunoun (1997), Buruli ulcers in rural areas in Benin: management of 635 cases, Med. Too Much, 37, 83-90.

      [4] Kanga J M and Kacou E D. (2001), Epidemiological Aspects of Buruli ulcer in Côte d'ivoire: Results of a national Survey, Bull Soc Pathol Exot, 94,46-51.

      [5] Kibadi K, Tsakala T M, Mputu-yamba J B, Muyembe T, Kashongwe M (2003). Buruli ulcer in Angolan refugees from the sites of Kimpese, Central Congo (R D Congo). Health notebooks, 13,40-43.

      [6] Muelder K, and Noukou A (1990). Buruli ulcer in Benin the Lancet. 336, 1109-1111. https://doi.org/10.1016/0140-6736(90)92581-2.

      [7] Perquis P, Muret G, Ravisse P and Maydat L (1968). – Tropical Mycobacterial ulcers about 8 observations. Med too, 26,642-648.

      [8] Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, Aubry J, Nuermberger E, Grosset J. 2007 Nov. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother;51(11):4029-4035. https://doi.org/10.1128/AAC.00175-07.

      [9] Kibadi K, Tsakala TM, Mputu YJ, Muyembe T, Kashongwe M and Imposo B. (2002), Therapeutic trial of the association Chloramine, Furantoine, metronidazole in the local treatment and the ulcer of Buruli over infected. Med. Afr. Black, 49, 239-243.

      [10] George K.M., Barker L. P, Welty D.M., Small P.L. (1998), Partial purification and Characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infection and Immunity, 66,587-593. https://doi.org/10.1128/IAI.66.2.587-593.1998.

      [11] George K M., Chatterjee D., Gunawardana G., Welty D., Hayman J., Lee R., and Small P.L. (1999), Mycolactone: A polyketide toxin from Mycobacterium ulcerans required for virulence. Science, 283:854-857 https://doi.org/10.1126/science.283.5403.854.

      [12] Kabedi B.M., Kayembe N.J., Kashongwe M.Z, Bisouta F.S, Mampasi K.P, Mbaya K.P, Taba K.M, Mifundu M N, Mulenga M.C, Nkasa L.H, Tshitadi M. A, Nganga N.M and Muyembe T.J.J (2018), in vitro Evaluation of Mycobacterial activity of Phytomedicine Mathesia on Mycobacterium tuberculosis, Medical and clinical Reviews, vol. 4 No. 2:5.

      [13] Anonymous (2010) Clinical toxicologists Coordinating Committee: Gamma Butyrolactone: Retrospective study of the observations notified between 2005 and 2009.

      [14] Sivilotti M. L, Burns M J, Aaron C K, Greenberg M. J (2001). Pentobarbital for severe gamma Butyrolactone with drawal. Ann Emerg Med; 38 (6): 660-665. https://doi.org/10.1067/mem.2001.119454.

      [15] Mostafa Ghobashy, Mambouh Gadallah, Tamer T. El-Idreesy, M. A. Sadek , Hany A. using caustic soda, international journal of Engineering & Technology,7(4)1995-1999. https://doi.org/10.14419/ijet.v7i4.14083.

      [16] Pierre Aubry P, Gauzere B.A. Updated on 08/10/2015. Buruli Ulcer News 2015. Degree in tropical Medicine from the countries of the Indian Ocean.

      [17] WHO, (2009) Treatment of Mycobacterium ulcerans infection (Buruli ulcer).

  • Downloads

  • How to Cite

    H. Nkasa, L., C. Mulenga, M., J. Muzomwe, M., J. Kayembe, S., B. Ilinga, L., Z. Kashongwe, M., P. Ngoy, B., & M Taba, K. (2022). Kinetics studies of phytomedicine mathesia - -butyrolactone interaction. International Journal of Engineering & Technology, 11(1), 73-77. https://doi.org/10.14419/ijet.v11i1.32057